BACKGROUND: Endogenous ouabain (EO) has been linked with long-term changes in sodium balance and cardiovascular structure and function. The biosynthesis of EO involves, cholesterol side-chain cleavage (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (HSD3B) with sequential metabolism of pregnenolone and progesterone. Furthermore, the renal excretion of cardiac glycosides is mediated by the organic anion transporter (SLCO4C1) at the basolateral membrane and the P-glycoprotein (PGP) (encoded by MDR1) at the apical membrane of the nephron. METHODS: Average 24-h ambulatory blood pressures were recorded in 729 untreated essential hypertensives. Aldosterone (Aldo), EO, urinary Na+, and K+ excretions were determined. Single-nucleotide polymorphism (SNP) and haplotype-based association study was performed with a total of 26 informative SNPs. RESULTS: Plasma EO was significantly directly related to both day (r = 0.131, P < 0.01) and nighttime diastolic blood pressure (DBP) (r = 0.143, P < 0.01), and remained significantly related after correction for confounders (sex, body mass index, age). Genotype analysis for EO levels and daytime DBP gave significant results for CYP11A1 rs11638442 and MDR1 rs1045642 (T/C Ile1145) in which the minor allele tracked with higher EO levels (T/T 210.3 (147-272) vs. C/C 270.7 (193-366) pmol/l, P < 0.001). Association was found between HSD3B1 polymorphisms and/or haplotypes with blood pressure (systolic blood pressure (SBP) 140.3 (11.7) vs. 143.8 (11.2) mm Hg, P < 0.01) and plasma Aldo (P < 0.05). Haplotype-based analyses support the data of SNP analysis. CONCLUSIONS: Among patients with essential hypertension, cholesterol side-chain cleavage and MDR1 loci are related to circulating EO and DBP, most likely by influencing EO synthesis and transmembrane transport, respectively. In contrast, variants in HSD3B1 are related with SBP probably via Aldo.
BACKGROUND: Endogenous ouabain (EO) has been linked with long-term changes in sodium balance and cardiovascular structure and function. The biosynthesis of EO involves, cholesterol side-chain cleavage (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (HSD3B) with sequential metabolism of pregnenolone and progesterone. Furthermore, the renal excretion of cardiac glycosides is mediated by the organic anion transporter (SLCO4C1) at the basolateral membrane and the P-glycoprotein (PGP) (encoded by MDR1) at the apical membrane of the nephron. METHODS: Average 24-h ambulatory blood pressures were recorded in 729 untreated essential hypertensives. Aldosterone (Aldo), EO, urinary Na+, and K+ excretions were determined. Single-nucleotide polymorphism (SNP) and haplotype-based association study was performed with a total of 26 informative SNPs. RESULTS: Plasma EO was significantly directly related to both day (r = 0.131, P < 0.01) and nighttime diastolic blood pressure (DBP) (r = 0.143, P < 0.01), and remained significantly related after correction for confounders (sex, body mass index, age). Genotype analysis for EO levels and daytime DBP gave significant results for CYP11A1rs11638442 and MDR1rs1045642 (T/C Ile1145) in which the minor allele tracked with higher EO levels (T/T 210.3 (147-272) vs. C/C 270.7 (193-366) pmol/l, P < 0.001). Association was found between HSD3B1 polymorphisms and/or haplotypes with blood pressure (systolic blood pressure (SBP) 140.3 (11.7) vs. 143.8 (11.2) mm Hg, P < 0.01) and plasma Aldo (P < 0.05). Haplotype-based analyses support the data of SNP analysis. CONCLUSIONS: Among patients with essential hypertension, cholesterol side-chain cleavage and MDR1 loci are related to circulating EO and DBP, most likely by influencing EO synthesis and transmembrane transport, respectively. In contrast, variants in HSD3B1 are related with SBP probably via Aldo.
Authors: Andreas Johne; Karla Köpke; Thomas Gerloff; Ingrid Mai; Stephan Rietbrock; Christian Meisel; Sven Hoffmeyer; Reinhold Kerb; Martin F Fromm; Ulrich Brinkmann; Michel Eichelbaum; Jürgen Brockmöller; Ingolf Cascorbi; Ivar Roots Journal: Clin Pharmacol Ther Date: 2002-11 Impact factor: 6.875
Authors: Marianne B Müller; Martin E Keck; Elisabeth B Binder; Adelheid E Kresse; Thomas P Hagemeyer; Rainer Landgraf; Florian Holsboer; Manfred Uhr Journal: Neuropsychopharmacology Date: 2003-11 Impact factor: 7.853
Authors: Ji-Guang Wang; Jan A Staessen; Elisabetta Messaggio; Tim Nawrot; Robert Fagard; John M Hamlyn; Giuseppe Bianchi; Paolo Manunta Journal: J Hypertens Date: 2003-08 Impact factor: 4.844
Authors: Helen J L Speirs; Ksenia Katyk; Natasha N Kumar; Adam V Benjafield; William Y S Wang; Brian J Morris Journal: J Hypertens Date: 2004-05 Impact factor: 4.844
Authors: Paolo Manunta; Marc Maillard; Cristina Tantardini; Marco Simonini; Chiara Lanzani; Lorena Citterio; Paola Stella; Nunzia Casamassima; Michel Burnier; John M Hamlyn; Giuseppe Bianchi Journal: J Hypertens Date: 2008-05 Impact factor: 4.844
Authors: Paolo Manunta; John M Hamlyn; Marco Simonini; Elisabetta Messaggio; Chiara Lanzani; Maria Bracale; Giuseppe Argiolas; Nunzia Casamassima; Elena Brioni; Nicola Glorioso; Giuseppe Bianchi Journal: J Hypertens Date: 2011-02 Impact factor: 4.844
Authors: Cristina I Linde; Laura K Antos; Vera A Golovina; Mordecai P Blaustein Journal: Am J Physiol Heart Circ Physiol Date: 2012-07-27 Impact factor: 4.733